Stock INDEX INDEX PHARMACEUTICALS HOLDING AB
Add to a list
To use this feature you must be a member
Log inSign up

Other languages InDex Pharmaceuticals Holding AB

Equities

INDEX

SE0008966295

Delayed Nasdaq Stockholm
Other stock markets
 08:19:22 2024-04-29 EDT 		5-day change 1st Jan Change
0.374 SEK +1.63% Intraday chart for InDex Pharmaceuticals Holding AB +7.16% +46.09%
04-26 InDex Pharmaceuticals Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-05 Index Pharmaceuticals Holding AB Announces Board Resignations CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
InDex Pharmaceuticals Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024
Index Pharmaceuticals Holding AB Announces Board Resignations
InDex Pharmaceuticals CEO, CFO to Step Down as Operations Cease
Index Pharmaceuticals Holding AB Announces Resignation of Johan Giléus as Deputy CEO
InDex Pharmaceuticals Holding AB Announces Resignation of Jenny Sundqvist as CEO, Effective September 26, 2024
InDex Pharmaceuticals Launches Strategic Review Amid Decision to Stop Cobitolimod Development
InDex Pharmaceuticals Holding AB Discontinues the Development of Cobitolimod
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
InDex Pharmaceuticals Holding AB Discontinues Cobitolimod Phase III Program
InDex Pharmaceuticals Holding AB Announces Composition of the Nomination Committee
InDex Pharmaceuticals Holding AB Receives New Patent for Cobitolimod in South Korea
InDex Pharmaceuticals Holding AB Announces All Patients Needed for the Cobitolimod Dose Selection Milestone Have Completed Induction Study 1 of the Phase III Program Conclude
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
InDex Pharmaceuticals Holding AB Announces Positive Results from the Pharmacokinetic (PK) Study
InDex Pharmaceuticals Holding AB Announces New Formulation Patent for Drug Candidate Cobitolimod Grants by European Patent Office
InDex Pharmaceuticals Obtains New European Patent for Inflammatory Bowel Disease Drug
InDex Pharmaceuticals Holding AB Announces License Agreement with Viatris Japan to Develop and Commercialize Cobitolimod in Japan
InDex Pharmaceuticals Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INDEX Stock
  4. News InDex Pharmaceuticals Holding AB
  5. Other languages